SOUTH SAN FRANCISCO, Calif., April 16, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Patent & Trademark Office (USPTO) has issued to Hyperion U.S. patent number 8,404,215 entitled, METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS. The patent discloses optimal measurement timing and target levels for blood ammonia in urea cycle disorder (UCD) patients. The issued patent has a term that expires in March 2032. Hyperion plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book. Hyperion announced on February 2, 2013, the allowance of its patent application by the USPTO.
- RAVICTI is not indicated for the treatment of acute hyperammonemia (HA) in patients with UCD because more rapidly acting interventions are essential to reduce plasma ammonia levels.
- The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.
- Less than two months of age. Children less than two months of age may have immature pancreatic exocrine function which could impair hydrolysis of RAVICTI, leading to impaired absorption of phenylbutyrate and HA.
- With known hypersensitivity to phenylbutyrate. Signs of hypersensitivity include wheezing, shortness of breath, coughing, low blood pressure, flushing, nausea and rash.